Special Report: Biotech incubator taps investors through in-house brokerage

Special Report: Biotech incubator taps investors through in-house brokerage


In a research note posted on National's website, he rated the newly listed stock a "buy" and predicted that the share price would more than double in a year. ), with several cancer drugs in various stages of development.



from Biotech News